Correlation Between Eupraxia Pharmaceuticals and Monopar Therapeutics
Can any of the company-specific risk be diversified away by investing in both Eupraxia Pharmaceuticals and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eupraxia Pharmaceuticals and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eupraxia Pharmaceuticals and Monopar Therapeutics, you can compare the effects of market volatilities on Eupraxia Pharmaceuticals and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eupraxia Pharmaceuticals with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eupraxia Pharmaceuticals and Monopar Therapeutics.
Diversification Opportunities for Eupraxia Pharmaceuticals and Monopar Therapeutics
-0.44 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Eupraxia and Monopar is -0.44. Overlapping area represents the amount of risk that can be diversified away by holding Eupraxia Pharmaceuticals and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and Eupraxia Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eupraxia Pharmaceuticals are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of Eupraxia Pharmaceuticals i.e., Eupraxia Pharmaceuticals and Monopar Therapeutics go up and down completely randomly.
Pair Corralation between Eupraxia Pharmaceuticals and Monopar Therapeutics
Assuming the 90 days horizon Eupraxia Pharmaceuticals is expected to under-perform the Monopar Therapeutics. But the pink sheet apears to be less risky and, when comparing its historical volatility, Eupraxia Pharmaceuticals is 8.45 times less risky than Monopar Therapeutics. The pink sheet trades about -0.03 of its potential returns per unit of risk. The Monopar Therapeutics is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest 202.00 in Monopar Therapeutics on September 1, 2024 and sell it today you would earn a total of 2,051 from holding Monopar Therapeutics or generate 1015.35% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 54.28% |
| Values | Daily Returns |
Eupraxia Pharmaceuticals vs. Monopar Therapeutics
Performance |
| Timeline |
| Eupraxia Pharmaceuticals |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
| Monopar Therapeutics |
Eupraxia Pharmaceuticals and Monopar Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Eupraxia Pharmaceuticals and Monopar Therapeutics
The main advantage of trading using opposite Eupraxia Pharmaceuticals and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eupraxia Pharmaceuticals position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.| Eupraxia Pharmaceuticals vs. Akeso, Inc | Eupraxia Pharmaceuticals vs. Ascletis Pharma | Eupraxia Pharmaceuticals vs. Avax Techs | Eupraxia Pharmaceuticals vs. Eliem Therapeutics |
| Monopar Therapeutics vs. Tff Pharmaceuticals | Monopar Therapeutics vs. Eliem Therapeutics | Monopar Therapeutics vs. Inhibrx | Monopar Therapeutics vs. Enliven Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Complementary Tools
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |